Near-tetraploidy clone can evolve from a hyperdiploidy clone and cause resistance to lenalidomide and bortezomib in a multiple myeloma patient.

[1]  M. Dimopoulos,et al.  Treatment of Patients with Relapsed/Refractory Multiple Myeloma (MM) with Lenalidomide and Dexamethasone with or without Bortezomib: Prospective Evaluation of the Impact of Cytogenetic Abnormalities. , 2009 .

[2]  J. Aster,et al.  Divergent Effects of Notch Signaling On Leukemia Stem Cells and Hematopoietic Stem Cells. , 2009 .

[3]  P. L. Bergsagel,et al.  Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. , 2009, Blood.

[4]  Shi-feng Lu,et al.  Bortezomib in combination with dexamethasone for a young multiple myeloma with t(8; 14). , 2009, Leukemia research.

[5]  A. Al-Katib,et al.  Chromosome aberrations in a series of 120 multiple myeloma cases with abnormal karyotypes , 2007, American journal of hematology.

[6]  A. Nagler,et al.  Chromosome 13q deletion and IgH abnormalities may be both masked by near-tetraploidy in a high proportion of multiple myeloma patients: a combined morphology and I-FISH analysis. , 2007, Cancer letters.

[7]  R. Bataille,et al.  Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. , 2007, Blood.

[8]  H. Döhner,et al.  Cytogenetics and molecular cytogenetics in multiple myeloma. , 2006, European journal of cancer.

[9]  G. Ahmann,et al.  Ploidy status rarely changes in myeloma patients at disease progression. , 2006, Leukemia research.

[10]  Bart Barlogie,et al.  Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. , 2005, Blood.

[11]  Bart Barlogie,et al.  Genetics and Cytogenetics of Multiple Myeloma , 2004, Cancer Research.

[12]  S. Tanosaki,et al.  Near-triploidy and near-tetraploidy in hematological malignancies and mutation of the p53 gene. , 2004, Clinical and laboratory haematology.

[13]  R. Fonseca,et al.  The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma. , 2003, Blood.

[14]  R. Bataille,et al.  Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. , 2002, Blood.

[15]  R. Bataille,et al.  Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors. , 2001, Blood.

[16]  C. Bastard,et al.  Hypodiploidy is a major prognostic factor in multiple myeloma. , 2001, Blood.

[17]  P. L. Bergsagel,et al.  Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[18]  C. Bastard,et al.  Chromosomal analysis in multiple myeloma: cytogenetic evidence of two different diseases , 1998, Leukemia.

[19]  B. Barlogie,et al.  Cytogenetic findings in 200 patients with multiple myeloma. , 1995, Cancer genetics and cytogenetics.

[20]  R. Bataille,et al.  The retinoblastoma susceptibility gene RB-1 in multiple myeloma. , 1997, Leukemia & lymphoma.